Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Novartis to Cut 2,000 Jobs in Manufacturing, Development Division
October 28, 2011
- Hisamitsu Forms Chinese Subsidiary to Enter OTC Business
October 28, 2011
- JDF, Eli Lilly Japan Create Subsidy Program for Basic Incretin Research
October 28, 2011
- Nitto Denko, Maruho Apply for Additional Indication for Penles Tape for Pain Relief with Removal of Warts
October 28, 2011
- Bayer to Continue to Discuss Filing for Approval for Regorafenib in Europe, US after Improvement of OS in PIII Trial
October 28, 2011
- Baxter's Worldwide Sales Up 10% to US$10.3 Bil. for 1st Nine Months of 2011
October 28, 2011
- Terumo: Record Sales, Operating Profits in 1st Half of FY2011
October 28, 2011
- Nexium Tops HP Market in September Led by 2 Active Marketers: RepTrack Survey
October 27, 2011
- DSP to Distribute iPad2 to All MRs from Jan. Next Year
October 27, 2011
- Takara Bio Upwardly Revises Profit Forecasts for 1st Half of FY2012
October 27, 2011
- Sales of Top 30 Drug Wholesalers Up 1.9% in 2010: Yano Research Institute
October 27, 2011
- Wholesalers Expecting Some Increase in Price Gap in Next Market Price Survey
October 27, 2011
- GSK CEO Thinks Highly of Premiums for New Drug Creation, Key to Attractive Market
October 26, 2011
- Nippon Chemiphar Revises Business Forecasts for 1st Half of FY2012
October 26, 2011
- Perpetuation of Premium for New Drug Development Discussed at IMS Japan Symposium
October 26, 2011
- Wakamoto Revises the Full-Year Consolidated Forecasts Expecting Deficit Reduction
October 25, 2011
- MTPC Introduces 3-level Priority for Priority Products
October 25, 2011
- “Sales of Teribone Can Reach ¥10 Bil.”: President Asano of Asahi Kasei Pharma
October 25, 2011
- Mochida Upwardly Revises Business Forecasts for 1st Half of FY2012
October 25, 2011
- Biggest Challenge Is Decline in R&D Productivity: President Hasegawa of Takeda
October 25, 2011
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…